Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 10/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16252471 | 0.92 | ENPP2 (0.47) | SLC6A5ENPP2MCHR1DRD4DRD2 | |
| SCHEMBL116949 | 0.87 | SLC6A5 (0.55) | SLC6A5ENPP2ATXN2 | |
| SCHEMBL117453 | 0.84 | HRH3 (0.43) | ENPP2ATXN2 | |
| SCHEMBL117412 | 0.84 | HRH3 (0.43) | ENPP2ATXN2 | |
| SCHEMBL23252435 | 0.84 | ENPP2 (0.43) | ENPP2MCHR1DRD4ATXN2 | |
| SCHEMBL118275 | 0.81 | ENPP2 (0.45) | ENPP2MCHR1ATXN2 | |
| SCHEMBL23252420 | 0.80 | CRBN (0.49) | SLC6A5 | |
| SCHEMBL18464186 | 0.78 | ENPP2 (0.60) | ENPP2DRD4ATXN2 | |
| SCHEMBL18464309 | 0.77 | ENPP2 (0.60) | ENPP2DRD4ATXN2 | |
| SCHEMBL21323349 | 0.77 | ENPP2 (0.43) | ENPP2MCHR1ATXN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2623101-B1 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2021-04-21 | — | — | EP | disclosed |
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, PLA2G2E | SLC6A5 4376/4885ENPP2 1/4885MCHR1 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.